X
[{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Soligenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Beh\u00e7et's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals for Pentoxifylline
Filters
Companies By Therapeutic Area
Details:
Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), a treatment for oral ulcers in patients suffering from behcet's disease.
Lead Product(s):
Pentoxifylline
Therapeutic Area: Rare Diseases and Disorders
Product Name: Trental
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Poolbeg Pharma
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
April 30, 2024
Details:
Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.
Lead Product(s):
Pentoxifylline
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Trental-Generic
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 23, 2024
Details:
The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Lead Product(s):
Pentoxifylline
Therapeutic Area: Rare Diseases and Disorders
Product Name: SRT001
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Soligenix
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
May 01, 2023